Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "stent"

930 News Found

30 crore Ayushman cards created under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana
Healthcare | January 15, 2024

30 crore Ayushman cards created under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana

Beneficiaries can create Ayushman Card from their mobile phone using Ayushman App which has been downloaded 52 lakh times since its launch on 13th September, 2023


ARTBIO and PharmaLogic inks supply agreement for Lead-212 based Therapeutic Candidate for  treatment of prostate cancer
Supply Chain | January 15, 2024

ARTBIO and PharmaLogic inks supply agreement for Lead-212 based Therapeutic Candidate for treatment of prostate cancer

PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York


Tata Consumer Products to acquire Organic India
News | January 13, 2024

Tata Consumer Products to acquire Organic India

A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories


Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US
News | January 10, 2024

Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in US

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb


Caplin Group announces strategic investment of Rs. 700 crore in TN
News | January 09, 2024

Caplin Group announces strategic investment of Rs. 700 crore in TN

This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited


Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
Drug Approval | January 04, 2024

Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets

Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US


Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
News | January 02, 2024

Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn

Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)


Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment
Drug Approval | December 26, 2023

Wainua granted first-ever regulatory approval in the US for improving neuropathy impairment

US FDA approval based on NEURO-TTRansform Phase III results


Biocon Academy conducts 8th Graduation Day
News | December 19, 2023

Biocon Academy conducts 8th Graduation Day

Five batches across four programs of Biocon Academy participated in the graduation ceremony